EXXUA


What it isSelective 5-HT1A partial agonist with hERG blockade; major depression.
Why this oneIt produces antidepressant effects without serotonin-reuptake blockade, keeping sexual and weight effects relatively small.
What limits itModest efficacy, QT prolongation, and CYP3A4 interactions constrain use; the antidepressant suicidality warning applies.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Major depressive disorder | Adults | 18.2 mg QD | titrate to response | 72.6 mg QD |
| Major depressive disorder | Geriatric | 18.2 mg QD | 36.3 mg QD |
Titration Increase no sooner than Day 4, again after Day 7, then after 1 additional week
Renal CrCl <50 mL/min: start 18.2 mg QD; max 36.3 mg QD
Hepatic Moderate (Child-Pugh B): max 36.3 mg QD; severe: contraindicated
Available strengths
Pregnancy Insufficient human data; third-trimester exposure may cause PPHN and poor neonatal adaptation. Antidepressant pregnancy registry available.
Lactation Present in rat milk; no human data. Monitor infant for irritability, restlessness, somnolence, poor feeding, weight loss.
| Strength | #/mo | generic $/mo | brand $/mo | CostPlus | |
|---|---|---|---|---|---|
| 18.2 mg | ER tab | 30 qd | — | $1,724.13 | not offered |
| 36.3 mg | ER tab | 30 qd | — | not offered | |
| 54.5 mg | ER tab | 30 qd | — | $1,697.20 | not offered |
| 72.6 mg | ER tab | 30 qd | — | not offered |
Generic entry2037 est.
⚠ BOXED WARNING
Principal riskModest efficacy and QT prolongation
Legacy pregnancy categoryNot assigned — PLLR-era drug
Defining liabilitySexual/GI effects, hyponatremia, discontinuation and serotonin toxicity; overdose danger varies substantially by agent.